Podcasts about Bonilla

En la sección Sanamente, la psicóloga Susi Bonilla nos habla de la tolerancia en verano

Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss how to safely and smartly integrate AI into the clinical workflow and tap its potential to improve patient-centered care, drug development, and access to clinical trials. TRANSCRIPT Dr. Paul Hanona: Hello, I'm Dr. Paul Hanona, your guest host of the ASCO Daily News Podcast today. I am a medical oncologist as well as a content creator @DoctorDiscover, and I'm delighted to be joined today by Dr. Arturo Loaiza-Bonilla, the chief of hematology and oncology at St. Luke's University Health Network. Dr. Bonilla is also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies. Dr. Loaiza-Bonilla will share his unique perspective on the potential of artificial intelligence to advance precision oncology, especially through clinical trials and research, and other key advancements in AI that are transforming the oncology field. Our full disclosures are available in the transcript of the episode. Dr. Bonilla, it's great to be speaking with you today. Thanks for being here. Dr. Arturo Loaiza-Bonilla: Oh, thank you so much, Dr. Hanona. Paul, it's always great to have a conversation. Looking forward to a great one today. Dr. Paul Hanona: Absolutely. Let's just jump right into it. Let's talk about the way that we see AI being embedded in our clinical workflow as oncologists. What are some practical ways to use AI? Dr. Arturo Loaiza-Bonilla: To me, responsible AI integration in oncology is one of those that's focused on one principle to me, which is clinical purpose is first, instead of the algorithm or whatever technology we're going to be using. If we look at the best models in the world, they're really irrelevant unless we really solve a real day-to-day challenge, either when we're talking to patients in the clinic or in the infusion chair or making decision support. Currently, what I'm doing the most is focusing on solutions that are saving us time to be more productive and spend more time with our patients. So, for example, we're using ambient AI for appropriate documentation in real time with our patients. We're leveraging certain tools to assess for potential admission or readmission of patients who have certain conditions as well. And it's all about combining the listening of physicians like ourselves who are end users, those who create those algorithms, data scientists, and patient advocates, and even regulators, before they even write any single line of code. I felt that on my own, you know, entrepreneurial aspects, but I think it's an ethos that we should all follow. And I think that AI shouldn't be just bolted on later. We always have to look at workflows and try to look, for example, at clinical trial matching, which is something I'm very passionate about. We need to make sure that first, it's easier to access for patients, that oncologists like myself can go into the interface and be able to pull the data in real time when you really need it, and you don't get all this fatigue alerts. To me, that's the responsible way of doing so. Those are like the opportunities, right? So, the challenge is how we can make this happen in a meaningful way – we're just not reacting to like a black box suggestion or something that we have no idea why it came up to be. So, in terms of success – and I can tell you probably two stories of things that we know we're seeing successful – we all work closely with radiation oncologists, right? So, there are now these tools, for example, of automated contouring in radiation oncology, and some of these solutions were brought up in different meetings, including the last ASCO meeting. But overall, we know that transformer-based segmentation tools; transformer is just the specific architecture of the machine learning algorithm that has been able to dramatically reduce the time for colleagues to spend allotting targets for radiation oncology. So, comparing the target versus the normal tissue, which sometimes it takes many hours, now we can optimize things over 60%, sometimes even in minutes. So, this is not just responsible, but it's also an efficiency win, it's a precision win, and we're using it to adapt even mid-course in response to tumor shrinkage. Another success that I think is relevant is, for example, on the clinical trial matching side. We've been working on that and, you know, I don't want to preach to the choir here, but having the ability for us to structure data in real time using these tools, being able to extract information on biomarkers, and then show that multi-agentic AI is superior to what we call zero-shot or just throwing it into ChatGPT or any other algorithm, but using the same tools but just fine-tuned to the point that we can be very efficient and actually reliable to the level of almost like a research coordinator, is not just theory. Now, it can change lives because we can get patients enrolled in clinical trials and be activated in different places wherever the patient may be. I know it's like a long answer on that, but, you know, as we talk about responsible AI, that's important. And in terms of what keeps me up at night on this: data drift and biases, right? So, imaging protocols, all these things change, the lab switch between different vendors, or a patient has issues with new emerging data points. And health systems serve vastly different populations. So, if our models are trained in one context and deployed in another, then the output can be really inaccurate. So, the idea is to become a collaborative approach where we can use federated learning and patient-centricity so we can be much more efficient in developing those models that account for all the populations, and any retraining that is used based on data can be diverse enough that it represents all of us and we can be treated in a very good, appropriate way. So, if a clinician doesn't understand why a recommendation is made, as you probably know, you probably don't trust it, and we shouldn't expect them to. So, I think this is the next wave of the future. We need to make sure that we account for all those things. Dr. Paul Hanona: Absolutely. And even the part about the clinical trials, I want to dive a little bit more into in a few questions. I just kind of wanted to make a quick comment. Like you said, some of the prevalent things that I see are the ambient scribes. It seems like that's really taken off in the last year, and it seems like it's improving at a pretty dramatic speed as well. I wonder how quickly that'll get adopted by the majority of physicians or practitioners in general throughout the country. And you also mentioned things with AI tools regarding helping regulators move things quicker, even the radiation oncologist, helping them in their workflow with contouring and what else they might have to do. And again, the clinical trials thing will be quite interesting to get into. The first question I had subsequent to that is just more so when you have large datasets. And this pertains to two things: the paper that you published recently regarding different ways to use AI in the space of oncology referred to drug development, the way that we look at how we design drugs, specifically anticancer drugs, is pretty cumbersome. The steps that you have to take to design something, to make sure that one chemical will fit into the right chemical or the structure of the molecule, that takes a lot of time to tinker with. What are your thoughts on AI tools to help accelerate drug development? Dr. Arturo Loaiza-Bonilla: Yes, that's the Holy Grail and something that I feel we should dedicate as much time and effort as possible because it relies on multimodality. It cannot be solved by just looking at patient histories. It cannot be solved by just looking at the tissue alone. It's combining all these different datasets and being able to understand the microenvironment, the patient condition and prior treatments, and how dynamic changes that we do through interventions and also exposome – the things that happen outside of the patient's own control – can be leveraged to determine like what's the best next step in terms of drugs. So, the ones that we heard the news the most is, for example, the Nobel Prize-winning [for Chemistry awarded to Demis Hassabis and John Jumper for] AlphaFold, an AI system that predicts protein structures right? So, we solved this very interesting concept of protein folding where, in the past, it would take the history of the known universe, basically – what's called the Levinthal's paradox – to be able to just predict on amino acid structure alone or the sequence alone, the way that three-dimensionally the proteins will fold. So, with that problem being solved and the Nobel Prize being won, the next step is, “Okay, now we know how this protein is there and just by sequence, how can we really understand any new drug that can be used as a candidate and leverage all the data that has been done for many years of testing against a specific protein or a specific gene or knockouts and what not?” So, this is the future of oncology and where we're probably seeing a lot of investments on that. The key challenge here is mostly working on the side of not just looking at pathology, but leveraging this digital pathology with whole slide imaging and identifying the microenvironment of that specific tissue. There's a number of efforts currently being done. One isn't just H&E, like hematoxylin and eosin, slides alone, but with whole imaging, now we can use expression profiles, spatial transcriptomics, and gene whole exome sequencing in the same space and use this transformer technology in a multimodality approach that we know already the slide or the pathology, but can we use that to understand, like, if I knock out this gene, how is the microenvironment going to change to see if an immunotherapy may work better, right? If we can make a microenvironment more reactive towards a cytotoxic T cell profile, for example. So, that is the way where we're really seeing the field moving forward, using multimodality for drug discovery. So, the FDA now seems to be very eager to support those initiatives, so that's of course welcome. And now the key thing is the investment to do this in a meaningful way so we can see those candidates that we're seeing from different companies now being leveraged for rare disease, for things that are going to be almost impossible to collect enough data, and make it efficient by using these algorithms that sometimes, just with multiple masking – basically, what they do is they mask all the features and force the algorithm to find solutions based on the specific inputs or prompts we're doing. So, I'm very excited about that, and I think we're going to be seeing that in the future. Dr. Paul Hanona: So, essentially, in a nutshell, we're saying we have the cancer, which is maybe a dandelion in a field of grass, and we want to see the grass that's surrounding the dandelion, which is the pathology slides. The problem is, to the human eye, it's almost impossible to look at every single piece of grass that's surrounding the dandelion. And so, with tools like AI, we can greatly accelerate our study of the microenvironment or the grass that's surrounding the dandelion and better tailor therapy, come up with therapy. Otherwise, like you said, to truly generate a drug, this would take years and years. We just don't have the throughput to get to answers like that unless we have something like AI to help us. Dr. Arturo Loaiza-Bonilla: Correct. Dr. Paul Hanona: And then, clinical trials. Now, this is an interesting conversation because if you ever look up our national guidelines as oncologists, there's always a mention of, if treatment fails, consider clinical trials. Or in the really aggressive cancers, sometimes you might just start out with clinical trials. You don't even give the standard first-line therapy because of how ineffective it is. There are a few issues with clinical trials that people might not be aware of, but the fact that the majority of patients who should be on clinical trials are never given the chance to be on clinical trials, whether that's because of proximity, right, they might live somewhere that's far from the institution, or for whatever reason, they don't qualify for the clinical trial, they don't meet the strict inclusion criteria.  But a reason you mentioned early on is that it's simply impossible for someone to be aware of every single clinical trial that's out there. And then even if you are aware of those clinical trials, to actually find the sites and put in the time could take hours. And so, how is AI going to revolutionize that? Because in my mind, it's not that we're inventing a new tool. Clinical trials have always been available. We just can't access them. So, if we have a tool that helps with access, wouldn't that be huge? Dr. Arturo Loaiza-Bonilla: Correct. And that has been one of my passions. And for those who know me and follow me and we've spoke about it in different settings, that's something that I think we can solve. This other paradox, which is the clinical trial enrollment paradox, right? We have tens of thousands of clinical trials available with millions of patients eager to learn about trials, but we don't enroll enough and many trials close to accrual because of lack of enrollment. It is completely paradoxical and it's because of that misalignment because patients don't know where to go for trials and sites don't know what patients they can help because they haven't reached their doors yet. So, the solution has to be patient-centric, right? We have to put the patient at the center of the equation. And that was precisely what we had been discussing during the ASCO meeting. There was an ASCO Education Session where we talked about digital prescreening hubs, where we, in a patient-centric manner, the same way we look for Uber, Instacart, any solution that you may think of that you want something that can be leveraged in real time, we can use these real-world data streams from the patient directly, from hospitals, from pathology labs, from genomics companies, to continuously screen patients who can match to the inclusion/exclusion criteria of unique trials. So, when the patient walks into the clinic, the system already knows if there's a trial and alerts the site proactively. The patient can actually also do decentralization. So, there's a number of decentralized clinical trial solutions that are using what I call the “click and mortar” approach, which is basically the patient is checking digitally and then goes to the site to activate. We can also have the click and mortar in the bidirectional way where the patient is engaged in person and then you give the solution like the ones that are being offered on things that we're doing at Massive Bio and beyond, which is having the patient to access all that information and then they make decisions and enroll when the time is right.  As I mentioned earlier, there is this concept drift where clinical trials open and close, the patient line of therapy changes, new approvals come in and out, and sites may not be available at a given time but may be later. So, having that real-time alerts using tools that are able already to extract data from summarization that we already have in different settings and doing this natural language ingestion, we can not only solve this issue with manual chart review, which is extremely cumbersome and takes forever and takes to a lot of one-time assessments with very high screen failures, to a real-time dynamic approach where the patient, as they get closer to that eligibility criteria, they get engaged. And those tools can be built to activate trials, audit trials, and make them better and accessible to patients. And something that we know is, for example, 91%-plus of Americans live close to either a pharmacy or an imaging center. So, imagine that we can potentially activate certain of those trials in those locations. So, there's a number of pharmacies, special pharmacies, Walgreens, and sometimes CVS trying to do some of those efforts. So, I think the sky's the limit in terms of us working together. And we've been talking with corporate groups, they're all interested in those efforts as well, to getting patients digitally enabled and then activate the same way we activate the NCTN network of the corporate groups, that are almost just-in-time. You can activate a trial the patient is eligible for and we get all these breakthroughs from the NIH and NCI, just activate it in my site within a week or so, as long as we have the understanding of the protocol. So, using clinical trial matching in a digitally enabled way and then activate in that same fashion, but not only for NCTN studies, but all the studies that we have available will be the key of the future through those prescreening hubs. So, I think now we're at this very important time where collaboration is the important part and having this silo-breaking approach with interoperability where we can leverage data from any data source and from any electronic medical records and whatnot is going to be essential for us to move forward because now we have the tools to do so with our phones, with our interests, and with the multiple clinical trials that are coming into the pipelines. Dr. Paul Hanona: I just want to point out that the way you described the process involves several variables that practitioners often don't think about. We don't realize the 15 steps that are happening in the background. But just as a clarifier, how much time is it taking now to get one patient enrolled on a clinical trial? Is it on the order of maybe 5 to 10 hours for one patient by the time the manual chart review happens, by the time the matching happens, the calls go out, the sign-up, all this? And how much time do you think a tool that could match those trials quicker and get you enrolled quicker could save? Would it be maybe an hour instead of 15 hours? What's your thought process on that? Dr. Arturo Loaiza-Bonilla: Yeah, exactly. So one is the matching, the other one is the enrollment, which, as you mentioned, is very important. So, it can take, from, as you said, probably between 4 days to sometimes 30 days. Sometimes that's how long it takes for all the things to be parsed out in terms of logistics and things that could be done now agentically. So, we can use agents to solve those different steps that may take multiple individuals. We can just do it as a supply chain approach where all those different steps can be done by a single agent in a simultaneous fashion and then we can get things much faster. With an AI-based solution using these frontier models and multi-agentic AI – and we presented some of this data in ASCO as well – you can do 5,000 patients in an hour, right? So, just enrolling is going to be between an hour and maximum enrollment, it could be 7 days for those 5,000 patients if it was done at scale in a multi-level approach where we have all the trials available. Dr. Paul Hanona: No, definitely a very exciting aspect of our future as oncologists. It's one thing to have really neat, novel mechanisms of treatment, but what good is it if we can't actually get it to people who need it? I'm very much looking for the future of that.  One of the last questions I want to ask you is another prevalent way that people use AI is just simply looking up questions, right? So, traditionally, the workflow for oncologists is maybe going on national guidelines and looking up the stage of the cancer and seeing what treatments are available and then referencing the papers and looking at who was included, who wasn't included, the side effects to be aware of, and sort of coming up with a decision as to how to treat a cancer patient. But now, just in the last few years, we've had several tools become available that make getting questions easier, make getting answers easier, whether that's something like OpenAI's tools or Perplexity or Doximity or OpenEvidence or even ASCO has a Guidelines Assistant as well that is drawing from their own guidelines as to how to treat different cancers. Do you see these replacing traditional sources? Do you see them saving us a lot more time so that we can be more productive in clinic? What do you think is the role that they're going to play with patient care? Dr. Arturo Loaiza-Bonilla: Such a relevant question, particularly at this time, because these AI-enabled query tools, they're coming left and right and becoming increasingly common in our daily workflows and things that we're doing. So, traditionally, when we go and we look for national guidelines, we try to understand the context ourselves and then we make treatment decisions accordingly. But that is a lot of a process that now AI is helping us to solve. So, at face value, it seems like an efficiency win, but in many cases, I personally evaluate platforms as the chief of hem/onc at St. Luke's and also having led the digital engagement things through Massive Bio and trying to put things together, I can tell you this: not all tools are created equal. In cancer care, each data point can mean the difference between cure and progression, so we cannot really take a lot of shortcuts in this case or have unverified output. So, the tools are helpful, but it has to be grounded in truth, in trusted data sources, and they need to be continuously updated with, like, ASCO and NCCN and others. So, the reason why the ASCO Guidelines Assistant, for instance, works is because it builds on all these recommendations, is assessed by end users like ourselves. So, that kind of verification is critical, right? We're entering a phase where even the source material may be AI-generated. So, the role of human expert validation is really actually more important, not less important. You know, generalist LLMs, even when fine-tuned, they may not be enough. You can pull a few API calls from PubMed, etc., but what we need now is specialized, context-aware, agentic tools that can interpret multimodal and real-time clinical inputs. So, something that we are continuing to check on and very relevant to have entities and bodies like ASCO looking into this so they can help us to be really efficient and really help our patients. Dr. Paul Hanona: Dr. Bonilla, what do you want to leave the listener with in terms of the future direction of AI, things that we should be cautious about, and things that we should be optimistic about? Dr. Arturo Loaiza-Bonilla: Looking 5 years ahead, I think there's enormous promise. As you know, I'm an AI enthusiast, but always, there's a few priorities that I think – 3 of them, I think – we need to tackle head-on. First is algorithmic equity. So, most AI tools today are trained on data from academic medical centers but not necessarily from community practices or underrepresented populations, particularly when you're looking at radiology, pathology, and what not. So, those blind spots, they need to be filled, and we can eliminate a lot of disparities in cancer care. So, those frameworks to incentivize while keeping the data sharing using federated models and things that we can optimize is key. The second one is the governance on the lifecycle. So, you know, AI is not really static. So, unlike a drug that is approved and it just, you know, works always, AI changes. So, we need to make sure that we have tools that are able to retrain and recall when things degrade or models drift. So, we need to use up-to-date AI for clinical practice, so we are going to be in constant revalidation and make it really easy to do. And lastly, the human-AI interface. You know, clinicians don't need more noise or we don't need more black boxes. We need decision support that is clear, that we can interpret, and that is actionable. “Why are you using this? Why did we choose this drug? Why this dose? Why now?” So, all these things are going to help us and that allows us to trace evidence with a single click. So, I always call it back to the Moravec's paradox where we say, you know, evolution gave us so much energy to discern in the sensory-neural and dexterity. That's what we're going to be taking care of patients. We can use AI to really be a force to help us to be better clinicians and not to really replace us. So, if we get this right and we decide for transparency with trust, inclusion, etc., it will never replace any of our work, which is so important, as much as we want, we can actually take care of patients and be personalized, timely, and equitable. So, all those things are what get me excited every single day about these conversations on AI. Dr. Paul Hanona: All great thoughts, Dr. Bonilla. I'm very excited to see how this field evolves. I'm excited to see how oncologists really come to this field. I think with technology, there's always a bit of a lag in adopting it, but I think if we jump on board and grow with it, we can do amazing things for the field of oncology in general. Thank you for the advancements that you've made in your own career in the field of AI and oncology and just ultimately with the hopeful outcomes of improving patient care, especially cancer patients. Dr. Arturo Loaiza-Bonilla: Thank you so much, Dr. Hanona. Dr. Paul Hanona: Thanks to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Arturo Loaiza-Bonilla @DrBonillaOnc Dr. Paul Hanona @DoctorDiscover on YouTube Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn    ASCO on BlueSky Disclosures: Paul Hanona: No relationships to disclose. Dr. Arturo-Loaiza-Bonilla: Leadership: Massive Bio Stock & Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, CardinalHealth, Pfizer, AstraZeneca, Medscape Speakers' Bureau: Guardant Health, Ipsen, AstraZeneca/Daiichi Sankyo, Natera

El PSOE critica el cierre de camas en el hospital Materno de Málaga "mientras hay 10.400 niños en lista de espera quirúrgica"

Sergio Pérez y David Vinuesa entrevistan al dibujante Adrián Bonilla responsable del cómic sobre Hércules. Alkaios, el cómic con acento español que redefine la leyenda de Hércules. Adrián Bonilla y Juanma Mallén firmaron en 2023 de la mano de la editorial Tengu uno de los cómics más revolucionarios e impactantes de los últimos años. Tanto por fondo como por forma. Con un apartado visual demoledor obra de Adrián se aupó a los primeros puesto del cómic nacional hace 2 años y ahora tras una espera que ha valido la pena tenemos ya en nuestras comictecas la segunda y definitiva entrega con Adrián como autor completo. Hércules. Aquí llamado Alkaios para ocultarse del resto de la humanidad y de los dioses. No es el héroe que todos esperamos que sea. Sus 12 trabajos fueron mentira y ahora veremos el desenlace final de su intento de redención. Pincha en el audio para descubrir todos los detalles y escuchar la entrevista completa a Adrián Bonilla.

In this episode of Hope Natural Health, Dr. Erin chats w/guest Nicole Bonilla about how to eat your way to calm by fueling your body and calming anxiety. Nicole Bonilla is the founder of Gentle Tummy, a blog dedicated to creating delicious, easy-to-follow recipes that are gluten-free, higher in protein, and lower in sugar. After experiencing significant health challenges, Nicole has developed a unique perspective on managing anxiety, digestive health, and creating food that promotes overall well-being. What sets her apart is her emphasis on the profound connection between digestive and mental health, sharing mindsets that make healthier choices easier and anxiety more manageable. While not a healthcare professional, Nicole brings a lifetime of practical experience raising a family of six children, offering real-world solutions that work in busy households. During this episode you will learn about: How anxiety manifests in the gut The importance of shifting your relationship with food to support your body Practical strategies for implementing healthier eating habits consistently Website: gentletummy.com Social Media: youtube & facebook: @gentletummy   For more on Dr. Erin: Work with Dr. Erin here: https://p.bttr.to/3E88ps4 Buy Dr. Erin's Supplements here: https://drerinellis.com/shop Get the Period Productivity Planner here:  https://www.amazon.com/dp/B0BBYBRT5Q?ref_=pe_3052080_397514860 Download the FREE Menstrual Cycle Nutrition Guide here: https://detox.drerinellis.com/ Watch The Free Video "7 Hormones Affecting Your Weight Loss Goals" here: https://weightloss.drerinellis.com/ Let's Be Friends: Follow Dr. Erin on Instagram: https://www.instagram.com/dr.erinellis/ Follow Dr. Erin on Facebook: https://www.facebook.com/drerinellisnmd Follow Dr. Erin on TikTok: https://www.tiktok.com/@dr.erinellis?lang=en Join the Fix My Period Private Facebook Group: https://www.facebook.com/groups/470429440943215 Bookmark Dr. Erin's Website: https://drerinellis.com/ Subscribe to Hope Natural Health on YouTube: https://www.youtube.com/channel/UChHYVmNEu5tKu91EATHhEiA Follow Hope Natural Health on FB: https://www.facebook.com/hopenaturalhealth Sign up for Newsletters here: https://dashboard.mailerlite.com/forms/129653/99504448452166810/share Link to Testing: https://hopenaturalhealth.wellproz.com/   #GentleTummy #HormoneHealth #GutBrainAxis #WomensWellness #AnxietyRelief #GlutenFreeLiving #LowSugarRecipes #HighProtein #NaturopathicHealth #FoodAsMedicine #MindBodyConnection #HolisticNutrition #WomensHormones #HealthyEatingHabits #HopeNaturalHealth  

It's the most magical of baseball holidays: Bobby Bonilla Day! Baseball's most legendary deferred payment continues, and Pete has the updated list of players who will be cashing checks long after their cleats hit the shelf. Bobby may have been the first, but he's no longer alone.Meanwhile, the trade deadline is just a month away, but you'd never know it. After what looked like a hot start (Rafael Devers), the stove is lukewarm at best, and the rumor mill is oddly quiet. Should we be concerned, or are the GMs just waiting each other out?Both the Cardinals and Cubs are trending up, but with very different outlooks. Elliott and Pete are both on board with the Cubs buying — aggressively, if possible — but Ron is still waiting on the Cardinals to make good on their promise to clear the deck and let the kids take the wheel.Finally, peer pressure pays off, as Pete has agreed to watch Andor. Yes, really. But before you question his judgment, he redeems himself by delivering the finest outro in ToR history. You be the judge.Check out this week's livestream on YouTube, Rumble, Facebook, or X.Follow us on X and Instagram. Like us on Facebook.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Story #1: Will takes you on the latest round of 'Quick Takes,' delving into the Bryan Kohberger plea bargain, another round in President Donald Trump and Elon Musk's spate, and the online debate after video surfaces of Democrat New York City mayoral candidate Zohran Mamdani eating rice with his hands. Story #2: Former Chief Counsel For The House Judiciary Committee, Julian Epstein, joins Will to break down the future of the Democrat Party as they continue to head to the radical fringes of politics with Mamdani and how the two-party system is likely to reshape itself over the next decade.  Story #3: Happy Bobby Bonilla Day! Will and The Crew ask if Bonilla made the right choice when deferring his Mets' salary to 2011 and beyond. Tell Will what you thought about this podcast by emailing WillCainShow@fox.com Subscribe to 'Will Cain Country' on YouTube here: Watch Will Cain Country! Follow Will on X: @WillCain Learn more about your ad choices. Visit podcastchoices.com/adchoices

Happy Bonilla Day- every July 1st until 2035 Bonilla is set to collect $1.193 million from the NY Mets. Cody discusses the best CFB games (Tennessee vs Alabama???) Also, Danny White (UT AD) brings up a union for student athletes??? You can find the guys here: Jon: @jon__reed on X Cody: @Cody__McClure on X Don't forget to check out @fanrunsports on Instagram! or 'Fanrun TV' on Youtube. Might as well check out our Tik Tok, "Fanrun Radio" Lots of great writing over at www.fanrunradio.com

7:30AM Hour 2 Jeremy White and Joe DiBiase remember some of the craziest contracts in pro sports as they realize it's Bobby Bonilla day. They discuss the Bonilla contract, DiPietro's, and more!

Every year on July 1st, the Mets pay Bonilla $1.2 million

The New York Mets return home battered and bewildered after one of the ugliest stretches in franchise history. They've lost 15 of their last 18 games and just endured a humiliating sweep in Pittsburgh, where they were outscored 30-4 across three games—including a 12-1 blowout the day after a players-only meeting. It's July 1st—Bobby Bonilla Day—when the Mets famously cut that $1.19 million check yet again, symbolizing a franchise haunted by past decisions while the present crumbles around them. As the Mets open a critical 6-game homestand—three against the surging Milwaukee Brewers and three against the rival Yankees—questions abound. Has the team tuned out Carlos Mendoza? Will David Stearns pull the plug and become a deadline seller? Can the rotation rebound after getting lit up in Pittsburgh? And is there any hope left for this season? We'll dig deep into: Fallout from the Pirates sweep and what the players-only meeting achieved (if anything) Why Pete Alonso, Francisco Lindor, and Jeff McNeil are under the microscope The rotation woes and overworkBullpen How the Brewers and Yankees match up—and why this homestand could define the Mets' season A moment to reflect on Bobby Bonilla Day: the gift that keeps on giving Plus, updates from around MLB and what the latest rumors mean for the Mets' trade deadline plans. All this and more on today's episode!

Host Devin O'Shea and co-host Zack Spring, Matt Leonard, Michael Mancuso and Ross Levine discuss NBA Free Agency, Damian Lillard releasing, Shai and Jaren Jackson Jr extensions and more! Tuesday Trivia and the Stat of the Day!

¿Qué significa para el Centro de Estudios para el Desarrollo (CED) que el ex presidente Luis Lacalle Pou se haya sumado a su equipo? ¿En qué consiste el Programa de Alta Dirección de la Gestión Pública, que dirige Lacalle Pou, y que comenzó a dictarse con la participación de varios exministros en el plantel docente? Conversamos En Perspectiva con el economista Hernán Bonilla, presidente del CED, sobre estos temas y su nuevo libro Adam Smith: una introducción, que nos remonta a la Ilustración Escocesa.

#ElGranMusical | Jacinto Bonilla, Ecuador a su quinto Mundial: claves, desafíos y emociones by FM Mundo 98.1

En este episodio del podcast Blink de BBVA, Marco  Bonilla, responsable de Estrategia y Ejecución y de la Gestión del Conocimiento en Analytics Transformation en BBVA, comparte las claves del FinAI Summit 2025, el mayor evento de inteligencia artificial en el sector financiero organizado por la entidad. Con presencia en cuatro países y más de 6.000 inscritos, el FinAI Summit abordó temas críticos como la hiperpersonalización de servicios financieros mediante IA, la regulación y gobernanza de modelos, y la ética como pilar indispensable en el desarrollo tecnológico. Bonilla destaca cómo expertos como Kay Firth-Butterfield y Maya Ackerman ofrecieron reflexiones esenciales sobre los riesgos y el potencial creativo de esta tecnología, mientras que paneles y masterclasses reforzaron el compromiso de BBVA con una inteligencia artificial responsable, inclusiva y alinea (IA)da con la confianza del cliente.  

Conversación Digital Política en Costa Rica.

Candidata a ministra señala efecto distorsionador de acordeones en elecciónEnlace para apoyar vía Patreon:https://www.patreon.com/julioastilleroEnlace para hacer donaciones vía PayPal:https://www.paypal.me/julioastilleroCuenta para hacer transferencias a cuenta BBVA a nombre de Julio Hernández López: 1539408017CLABE: 012 320 01539408017 2Tienda:https://julioastillerotienda.com/ Hosted on Acast. See acast.com/privacy for more information.

Salud y Vida , invitados Dr . Luis Diego Cruz y Dr . Alejandro Bonilla

Analizamos en profundidad la cara B de las cloacas del Estado, los vínculos turbios entre sectores del PP, mandos policiales, tramas empresariales y los grandes medios de comunicación. Destapamos los audios, filtraciones y escándalos que apuntan a una guerra sucia para manipular la opinión pública, perseguir rivales políticos y proteger intereses económicos y partidistas. ¿Qué papel juegan Ayuso, Bonilla o el Grupo Planeta? ¿Qué se esconde tras la Operación Cataluña y el caso de los hidrocarburos? Una investigación que desvela cómo funciona el aparato oculto del poder en España. Mas vídeos de Pandemia Digital: https://www.youtube.com/c/PandemiaDigital1 Si quieres comprar buen aceite de primera prensada, sin intermediarios y ayudar de esa forma a los agricultores con salarios justos tenemos un código de promoción para ti: https://12coop.com/cupon/pandemiadigital/ Este video puede contener temas sensibles, así como discursos de odi*, ac*so, o discr*minación. El objetivo de abordar estos temas es exclusivamente informativo y busca concienciar a la audiencia sobre estos acontecimientos, y denunciar y señalar el origen de los mismos para crear consciencia y evitar su propagación. Si consideras que el contenido puede afectarte, te recomendamos proceder con precaución o evitar su visualización. ----------------------------------------------------------------------------------------------- Únete a nuestra comunidad de YouTube https://www.youtube.com/channel/UCFOwGZY-NTnctghtlHkj8BA/join Se mecenas de Patreon https://www.patreon.com/PandemiaDigital ----------------------------------------------------------------------------------------------- Súmate a la comunidad en Twitch - En vivo de Lunes a Jueves: https://www.twitch.tv/pandemiadigital Sigue nuestro Canal de Telegram: https://t.me/PandemiaDigital Suscríbete en nuestra web: https://PandemiaDigital.net Sigue nuestras redes: Twitter: https://twitter.com/PandemiaDigitaI Facebook: https://www.facebook.com/PandemiaDigitalObservatorio Instagram: https://www.instagram.com/pandemia_digital_twitch TikTok: https://www.tiktok.com/@pandemiadigital #PandemiaDigital

En este episodio EN ESPAÑOL, invitamos a Liscar Bonilla, fundadora de Amalactar y autora de su primer libro, "Amamantar y no rendirse en el intento: 100 consejos para mamás." En esta conversación, compartí mi propia experiencia de relactación, y Liscar nos brindó consejos invaluables sobre cómo navegar la lactancia como mamás latinas, y desmitificamos algunos mitos que han afectado mamás que desean amamantar.Lo que escucharás:Mi experiencia personal con la lactancia maternaLos 3 consejos más importantes de Liscar para una lactancia exitosaCómo desmitificar creencias dañinas como "la leche es agua"Estrategias reales para conciliar la lactancia materna y el trabajoPor qué necesitamos recursos en español para madres latinasPara obtener notas detalladas del episodio, visita vivalamami.com/episode128Recursos mencionados:Libro: "Lactancia materna y sin rendirse: 100 consejos para mamás"Léelo en KindleLiga de La Leche InternacionalTarjeta "Conozca sus derechos" de la extracción de leche materna en el trabajoCómo seguir a Liscar y Amalactar:Instagram: @liscarbonillaAmalactar Instagram: @amalactarSitio web: www.amalactar.comFacebook: @amalactarTikTok: @amalactar----------------------------------------------------------In this episode IN SPANISH, we invite Liscar Bonilla, founder of Amalactar and author of her first book, "Breastfeeding and NOT Giving Up! 100 Tips for first-time Moms." In this conversation, I shared my own relactation journey, and Liscar gave us invaluable advice on how to navigate breastfeeding as Latina moms, as well as debunk some myths that have plagued moms who want to breastfeed.What You'll Hear:My personal experience with breastfeedingLiscar's 3 most important tips for successful breastfeedingHow to debunk harmful beliefs like "milk is water"Real strategies for balancing breastfeeding and workWhy we need Spanish-language resources for Latina mothersFor detailed show notes, visit vivalamami.com/episode128Resources Mentioned:Physical Book in Spanish: "Lactancia materna y sin rendirse: 100 consejos para mamás"Read it in English on KindleLove this episode? Subscribe wherever you are listening, share this episode with an amiga, and leave a review⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Apple podcasts.Follow Viva la Mami on Instagram @vivalamamiJoin the ⁠⁠⁠⁠Viva la Mami newsletter⁠⁠⁠⁠ so you won't miss a thing!Have a suggestion for an episode topic? Click HEREHave a suggestion for a guest? Click HEREVisit the Viva la Mami Websitewww.vivalamami.comHave questions or want to connect? Email us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠podcast@vivalamami.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

See omnystudio.com/listener for privacy information.

Carlos Alsina reflexiona en su monólogo sobre los siete años que lleva Pedro Sánchez como Presidente del Gobierno de España. También ahonda sobre la supuesta conspiración del capitán Bonilla, de la UCO, contra los partidos de izquierdas y del bulo en el que se le iba a colocar una bomba lapa a Pedro Sánchez.

Dieter comenta junto a Pepe Gª Domínguez, Alejandro Vara y Mario Noya la actuación del Gobierno a pesar de desmontarse el bulo de la 'bomba lapa´.

Manuel Bonilla, president of the Fresno Teachers Association (FTA), is at the center of a controversy involving Fresno Unified School District (FUSD). Superintendent Misty Her allegedly ordered a dossier compiling fabricated quotes—possibly generated using AI—accusing FTA of personal attacks. Bonilla condemns the document as an attempt to silence criticism and called for disciplinary action against those responsible. The FTA is demanding accountability and considering legal action. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Guest | FTA President Manuel Bonilla | Accountability & Misinformation Fresno Unified claimed its teachers union engaged in personal attacks on Superintendent. It used ChatGPT to fabricate quotes. Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive --- Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Guest | FTA President Manuel Bonilla | Accountability & Misinformation Fresno Unified claimed its teachers union engaged in personal attacks on Superintendent. It used ChatGPT to fabricate quotes. Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive --- Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Hoy lunes, Chino Deportes se tomó El Tema del Día para hablar de la final del Clausura que consagró al Alianza. Nos contactamos con Elmer Bonilla, ex árbitro internacional, para analizar el polémico juego. Además, todo el fútbol europeo, F1, Roland Garros y la NBA.

Ingles | Español: Pastor Andres Bonilla nos habla de como deberia gobernar Dios en nuestros hogares para poder impactar a la comunidad a la que pertenecemos.

  “You make the best decision for yourself and your family—and you stick with it.”- Kim Pena What happens when you're handed unexpected news at your child's birth—and there's no clear roadmap ahead? In this reposted episode, educator and mom Kim Pena shares her powerful journey as the parent of a child born with Microtia Atresia, a rare congenital condition affecting the ear. Kim was one of Katie's very first guests on the Child Life On Call podcast, and her story is still a listener favorite to this day. In this repost, Katie kicks off the episode by giving us a quick update about Kim's son.  From discovering her son's diagnosis at birth to making emotional, high-stakes decisions about surgery and hearing aids, Kim walks us through her family's deeply personal experience with compassion, clarity, and humor. In this episode, you'll learn: ✅ What Microtia Atresia is and how it affects children ✅ How Kim and her husband navigated hearing loss, reconstructive surgery, and insurance battles ✅ Why early intervention with hearing aids changed everything ✅ What recovery and long-term care looked like for their son ✅ How to find trusted resources and support if your child is diagnosed   Kim's story offers encouragement, practical wisdom, and a reminder that joy often shines through the hardest moments. Timestamps & Key Topics ⏱️ [00:00] – Introduction: Meet Kim and Thomas Kim's background as an educator, and how her son's birth revealed an unexpected diagnosis ⏱️ [02:00] – What Is Microtia Atresia? Definition and how it affects the outer and middle ear Kim learns about the condition immediately after birth ⏱️ [04:00] – Family History and Diagnosis Challenges The connection to Kim's brother-in-law Why this condition wasn't caught on ultrasound ⏱️ [07:00] – Building a Support System How Kim's relationship with her father-in-law became essential Finding emotional and logistical support from someone who's been there ⏱️ [09:00] – First Surgeries and Hearing Tests Understanding Thomas's hearing loss The process of getting tested, hearing aids, and early therapy ⏱️ [11:00] – Choosing the Right Surgery Exploring different surgical options, including rib graft and Medpor Why Kim's family chose a single-surgery approach ⏱️ [13:00] – Surgery Day and Recovery A 13-hour surgery and the emotional toll Why recovery in California brought unexpected connections ⏱️ [16:00] – Post-Surgery Life & Daily Care What healing looked like in the months after Kim's advice on establishing trust, prepping a toddler, and using distraction ⏱️ [20:00] – The Bittersweet Nature of Change Letting go of “his little ear” Gratitude for what the journey has taught their family ⏱️ [22:00] – Research, Advocacy & Making Confident Choices The role of online communities and navigating defensiveness Why Kim recommends aiding early—and being unapologetic about your choices ⏱️ [27:00] – A Life-Changing Hearing Aid Moment The first time Thomas could hear clearly—how it changed their world Why Kim wishes she had recorded that moment ⏱️ [29:00] – Final Reflection: Raising a “Joy Boy” Despite everything, Thomas's joy and resilience shine through Why Kim's journey is one of perspective, peace, and purpose   Resources & Links

SummaryIn this episode of the Investing with Purpose podcast, host Steven Libman interviews Donna Bonilla, a mother, grandmother, and widow who shares her journey of faith-driven investing. Donna discusses her personal experiences with loss, the importance of tithing, and how her financial mindset has evolved over time. She emphasizes the significance of giving back to the community and the impact of her nonprofit, Not Forgotten Ministries, which supports widows. The conversation explores the intersection of profit and purpose in investing, highlighting the importance of aligning financial decisions with one's values and faith.Chapters00:00 Introduction to Faith-Driven Investing03:00 Donna's Personal Journey and Loss06:04 Foundations of Financial Mindset08:53 The Role of Tithing and Giving11:56 Investing with Purpose and Community Impact14:53 Navigating Investments After Loss18:03 The Intersection of Profit and Purpose21:02 The Nonprofit Mission and Its Impact23:46 Building a Legacy of Giving27:00 Influences and Mentorship in Investing30:00 Rapid Fire Round and Final ThoughtsResources MentionedChristian Motorcycle Associationhttps://www.notforgotten-ministries.org/Connect with us: Are you interested in joining a community of like-minded individuals who aspire to build true wealth through real estate passive investing? Go to IHG Investor Club to learn more!

Federico analiza la decisión de Feijóo de encargar la ponencia política del PP a Moreno Bonilla y Mañueco.

Happy Mother's Day! We sit down with Tiffany to discuss the many hats mothers wear. We walk through her life's journey and she explains how prioritizing time with intention works to balance the chaos of life motherhood undoubtedly brings.

This ep of Drawing Hive features a strong panel of illustrators and painters including Scott Anderson, Adam Gustavson, John English, and Raymond Bonilla. We make art inspired by the movie Sinners, and take a look back at the career and work of illustrator Brad Holland.Visual Arts Passage offers online mentorship programs in Illustration and Fine Arts, led by industry professionals to help you develop real-world skills and build a career doing what you love.Start Your Journey Today: www.visualartspassage.com/programWhy Choose Visual Arts Passage?

Manuel Bonilla ha sido parte del corazón musical de muchas generaciones. Con más de 50 años compartiendo canciones que hablan de fe, amor y esperanza, su voz ha acompañado a niños, familias e iglesias en toda Iberoamérica. Su música, sigue tocando corazones y recordándonos lo importante que es mantener viva nuestra fe. Esta episodio celebra su historia, su legado y todo lo que nos ha enseñado a través de sus canciones.

A senior Corrections staff member said high risk offenders - similar to the man who murdered Juliana Bonilla Herrera - are regularly being paroled from prison and into the community. An inquest into the Colombian woman's death continued in front of coroner Alexandra Cunninghame. Reporter Adam Burns was at the hearing.

El expresidente de la República Luis Lacalle Pou fue presentado el jueves pasado como asesor del Centro de Estudios para el Desarrollo (CED), un think tank liberal con lazos con el Partido Nacional, que preside el economista Hernán Bonilla. En un texto difundido en redes sociales, el CED valora como “un honor” esta incorporación, de la que dice: “Jerarquizará el trabajo de nuestro think tank y sin dudas nos permitirá desarrollar nuestra misión con mayor eficacia”. Continúa el comunicado: “Para una organización dedicada al análisis y propuesta de políticas públicas, contar con quien fue el último responsable de las decisiones más relevantes en Uruguay en los últimos cinco años resulta un enorme privilegio”. Según agregó el CED, Lacalle Pou se enfocará en este nuevo rol en la formación de líderes para el sector público, tanto políticos como para la alta dirección de la gestión pública; también trabajará como asesor senior de investigaciones e informes elaborados por el CED; y se desempeñará como conferencista nacional e internacional sobre políticas públicas y desarrollo. “La visión de Luis Lacalle Pou y la del CED es coincidente respecto a la importancia de la libertad para el desarrollo de las personas y del país, tanto a nivel económico como social”, concluyó el texto. ¿Cómo observaron los tertulianos esta noticia, ahora que hay más información sobre qué rol tendrá el exmandatario en estos años? Y, al mismo tiempo, ¿cómo ven el lugar que están teniendo este tipo de instituciones, de think tanks, en la política uruguaya? La Tertulia de los Lunes con Miguel Brechner, Amira Fagúndez, Martín Moraes y Gloria Robaina.

CAPÍTULO #388… Esta semana desempolvamos la máquina de escribir y el carrete de fotos para redactar la crónica de sucesos con un análisis especial dedicado a Contrapaso. Hablaremos del trabajazo con el que Teresa Valero se lanzó como autora completa, que recientemente ha estrenado su segunda parte, y que nos lleva a la España Franquista de los años 50 con un buen género detectivesco y periodístico. Además comentamos la actualidad del mundo del cómic, con todos los avances y las próximas novedades editoriales, y hablando de novedades toca hacer una buena tanda de reseñas. Hoy hablaremos de los 4 Fantásticos de Millar, lo nuevo de Tom King y Bilquis Evely con Helen de Wyndhorn, una aventuraza de piratas con Raven, el regreso del tándem por antonomasia del noir, la conclusión del Alkaios de Adrián Bonilla y muchísimo más. Gracias por estar al otro lado agentes ¡Nos oímos! NOTICIAS [00:03:57] Inmortal Thor acaba en su número 25 Dan Mora dibujará un Batman de estilo manga Aleta rescata las Historias de la Guerra de Garth Ennis Los 4 Fantásticos se enfrentan a Galactus y Silver Surfer en su primer tráiler. Reacciones a Daredevil Born Again Glenn Fabry anuncia que le queda poco tiempo de vida Próximos avances editoriales NOVEDADES Y RELECTURAS [01:02:46] Lonesome Marvel Must Have Los Vengadores Guerra Interminable Marvel Essentials Los 4 Fantásticos de Mark Millar DC Premiere Batman Helen de Wyndhorn Raven Las casas de los impíos Onoda. Último soldado imperial Elixir Estela Plateada. El día del juicio Star Wars - Jango Fett / Thrawn Alianzas Doraemon Destro Alkaios 2 CONTRAPASO [02:50:02] Volvemos al Madrid de mediados del siglo pasado en la obra de Teresa Valero como autora completa, que ya deslumbró en su primera y exitosa entrega. Sin perder de vista la situación social de la época, retomamos la vida del trío protagonista y nos acercamos a tramas que ponen de manifiesto la censura durante el franquismo y la lucha de un país por abrirse al mundo. Pero un peligroso asesino en serie va a complicar mucho las cosas, y tras las viñetas de cautivadora belleza de Valero nos enfrentaremos al lado más oscuro de la sociedad. CORREO DEL AGENTE [04:52:48] Leemos todos vuestros mensajes dejados en las redes y nuestra sección de la voz de los Agentes de Hydra, ¡Habla pueblo Habla! ¡Muchas gracias por escucharnos y todo vuestro apoyo y participación! Nuestro PODCAST ya está en el CANAL SECUNDARIO ¡Inflate a contenido comiquero aquí! https://www.youtube.com/@tomosygrapaspodcast Tomos y grapas es un medio de comunicación transmedia, disfruta de nuestros contenidos también en nuestra web, YouTube y redes sociales. VISITA TAMBIÉN NUESTRA LIBRERÍA En la Calle Alcalá 211 o nuestra TIENDA ONLINE con el mejor servicio y atención tiendatomosygrapas.com

EXCLUSIVE INTERVIEW: Manuel Bonilla/President of the Fresno Teachers Association discusses Misty Her named as Fresno Unified's next Superintendent. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

This is a special On Air Culture Cast Edition of Inwood Art Works On Air. Three of our favorite local artists were invited to share their thoughts and reflect on the state of the arts in Inwood and Northern Manhattan. Our guests are plein air painter, Elissa Gore, filmmaker, actor and comedian, Adam Elliott, and muralist and painter, Daniel Bonilla.Each of these artists are longtime residents of Inwood, and in their own way, have put a spotlight on arts and culture in our Uptown Community.  

Guest: MANUAL BONILLA – President, Fresno Teachers Association Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Guest: MANUAL BONILLA – President, Fresno Teachers Association Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Analizamos el Informe número 27 del Observatorio Digital de la U. Latina.

En este episodio me acompaña Diana Bonilla, psicóloga, educadora y madre de dos niñas autistas. Nos cuenta su historia, el camino que han recorrido juntas y las creencias personales y sociales que han tenido que cuestionar y transformar. Una historia llena de fuerza y resiliencia. Para ponerse en contacto con Diana: https://www.instagram.com/confia.diana.bonilla/ Para leer más de su experiencia: https://cronicasdediana.wordpress.com/ Para obtener materia gratuito: https://www.dianabonilla.net/regalo Suscríbete al boletín para recibir noticias de los episodios, eventos, libros, blog mercadería y mucho más. Ingresa a: cuestionandocreencias.com y se parte de esta Tribu de Almas Conscientes.NUESTRAS REDES Telegram: https://t.me/cuestionandocreenciasTikTok: https://www.tiktok.com/@cuestionandocreencias?_t=8pJiD2Wy1iw&_r=1Instagram: instagram.com/cuestionandocreenciasFacebook: facebook.com/cuestionandocreenciasMúsica: Wager With Angels - Nathan Moore Conviértete en miembro de este canal para disfrutar de ventajas:https://www.youtube.com/channel/UC_mBQgld8aMsDy5hr-2zQZA/join

INTERVIEW: Manuel Bonilla/Fresno Teachers Association discusses Fresno Unified School Districts plans to cut 30 minutes of instruction at 41 different schools. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Nios platican sobre la obra de teatro "Arte".See omnystudio.com/listener for privacy information.

Les tenemos preparado un programa super entretenido donde vamos a jugar, tener platicas muy interesantes muchos datos que no lo vas a creer.See omnystudio.com/listener for privacy information.

Envíanos un mensaje!Esta semana a petición de varias personas que me escribieron te hablo de uno de los narcos más notorios del área sur de Puerto Rico. En el episodio de hoy te hablo de Felipe Bonilla Romero, mejor conocido como Felo Bonilla, quien antes de ser vinculado al mundo del narcotráfico era un conocido comerciante ponceño.Fuentes de información y documentos adicionales disponibles en Patreon.Background Music: CO.AG MusicSi estás buscando un cambio de carrera o escalar al próximo nivel gerencial o ejecutivo, un buen resumé y buen perfil para LinkedIn será crucial. Los servicios de Career Branding son personalizados y conllevan una reunión telefónica para discutir la experiencia e identificar información que añada valor. Todo de manera confidencial. También trabajan resumés para el gobierno federal.  Comunícate con Career Branding al 787.300.7777 para más detalles o visita www.resumeprofesional.com.Este episodio también es traído a ustedes por Jabonera Don Gato. Los jabones Don Gato son hechos a mano, sin químicos dañinos ni detergentes. Elaborados con aceites naturales, esenciales y aromáticos, seguros para la piel. Pruébalos y siente la diferencia. Visítalos en jaboneradongato.com y utiliza el código "Crimepod" para obtener un 10% de descuento en tu compra.Puedes llamar a Fernando Fernández Investigador Privado y Forense con más de 17 años de experiencia a nivel local e internacional al 787-276-5619 o visítalo en: Fernando Fernandez PIEste episodio es traído a ustedes por Libros787.com. Ordena tus libros favoritos escritos por autores puertorriqueños desde la comodidad de tu casa. Utiliza el código promocional: CRIMEPODPR para que recibas envío gratuito en tu primera compra. Envíos a todas partes de Puerto Rico y Estados Unidos.Career Branding, Don Gato, FF & 787 Call to actionSupport the show

Feeling overwhelmed by the constant chaos around you? Like the world is on a never-ending loop of bad news, and you're stuck in fight or flight mode? You're not alone—and it doesn't have to be this way.In this episode, guest Lidia Bonilla talks about how understanding your nervous system can be the key to handling all that stress. We'll dive into polyvagal theory, a game-changer for recognizing how your body reacts to danger, safety, and everything in between. It's time to stop letting external chaos dictate how you feel inside. Whether you're burning out at work, feeling triggered by politics, or just done with all the noise, this conversation will help you reconnect with yourself and find a sense of peace—even when the world feels anything but safe.Sign Up for The NEXT Best Thing Community: https://startyourrewrite.com/the-next-best-thing-interestSubscribe to the NEXT Nuggets Newsletter: https://thenextbestthingact.com/Follow The NEXT Best Thing on IG @nextbestthingpodStay in touch with Lidia BonillaIG: https://www.instagram.com/lidiabonilladotcom/LinkedIn: https://www.linkedin.com/in/lidiabonilla999/Website: https://www.lidiabonilla.com/More on the Polyvegal Theory: https://www.youtube.com/watch?v=Cxn9SyW0DvM